396 related articles for article (PubMed ID: 25991583)
1. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
2. Acquired and intrinsic resistance to vemurafenib in BRAF
Zhang P; Kuil LE; Buil LCM; Freriks S; Beijnen JH; van Tellingen O; de Gooijer MC
FEBS Open Bio; 2024 Jan; 14(1):96-111. PubMed ID: 37953496
[TBL] [Abstract][Full Text] [Related]
3. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.
Trudel S; Odolczyk N; Dremaux J; Toffin J; Regnier A; Sevestre H; Zielenkiewicz P; Arnault JP; Gubler B
BMC Cancer; 2014 Sep; 14():727. PubMed ID: 25265970
[TBL] [Abstract][Full Text] [Related]
4. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
[TBL] [Abstract][Full Text] [Related]
5. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ; Gupta A; Middleton MR
Target Oncol; 2016 Aug; 11(4):557-63. PubMed ID: 26857260
[TBL] [Abstract][Full Text] [Related]
6. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract][Full Text] [Related]
7. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
Ascierto PA; Simeone E; Giannarelli D; Grimaldi AM; Romano A; Mozzillo N
J Transl Med; 2012 May; 10():107. PubMed ID: 22640478
[TBL] [Abstract][Full Text] [Related]
8. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.
Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR
Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157
[TBL] [Abstract][Full Text] [Related]
9. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M; Lorigan P; Sergi MC; Benannoune N; Serra P; Vitale MG; Giannarelli D; Arance AM; Couselo EM; Neyns B; Tucci M; Guida M; Spagnolo F; Rossi E; Occelli M; Queirolo P; Quaglino P; Depenni R; Merelli B; Placzke J; Di Giacomo AM; Del Vecchio M; Indini A; da Silva IP; Menzies AM; Long GV; Robert C; Rutkowski P; Ascierto PA
Eur J Cancer; 2024 Mar; 199():113542. PubMed ID: 38266540
[TBL] [Abstract][Full Text] [Related]
10. Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases.
Uhrig M; Sedlmair M; Schlemmer HP; Hassel JC; Ganten M
Cancer Imaging; 2013 Jul; 13(3):306-13. PubMed ID: 23876444
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy.
Chowdhary M; Patel KR; Danish HH; Lawson DH; Khan MK
Onco Targets Ther; 2016; 9():7149-7159. PubMed ID: 28003758
[TBL] [Abstract][Full Text] [Related]
12. MET receptor serves as a promising target in melanoma brain metastases.
Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.
Lei J; Wang W; Lin D; Zhu C; Jia W; Weng W; Liu X; Ma Y; Wang Z; Yang L; He X; He Y; Li Y
J Cancer Res Clin Oncol; 2024 Jan; 150(1):12. PubMed ID: 38231288
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA
Kozak K; Kowalik A; Gos A; Wasag B; Lugowska I; Jurkowska M; Krawczynska N; Kosela-Paterczyk H; Switaj T; Teterycz P; Klimczak A; Siedlecki JA; Chlopek M; Kalisz J; Limon J; Rutkowski P
Tumori; 2020 Feb; ():300891619900928. PubMed ID: 32026754
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.
Sherman WJ; Romiti E; Michaelides L; Moniz-Garcia D; Chaichana KL; Quiñones-Hinojosa A; Porter AB
Curr Treat Options Oncol; 2023 Dec; 24(12):1962-1977. PubMed ID: 38158477
[TBL] [Abstract][Full Text] [Related]
16. Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma.
Hagen B; Trinh VA
J Adv Pract Oncol; 2014; 5(6):400-10. PubMed ID: 26328215
[TBL] [Abstract][Full Text] [Related]
17. Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs.
Kraft T; Grützmann K; Meinhardt M; Meier F; Westphal D; Seifert M
Acta Neuropathol Commun; 2024 Apr; 12(1):67. PubMed ID: 38671536
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
[TBL] [Abstract][Full Text] [Related]
19. Predicting the BRAF mutation with pretreatment MRI radiomics features for melanoma brain metastases receiving Gamma Knife radiosurgery.
Kawahara D; Jensen A; Yuan J; Nagata Y; Watanabe Y
Clin Radiol; 2023 Dec; 78(12):e934-e940. PubMed ID: 37690975
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of vemurafenib in children with recurrent or progressive BRAF
Nicolaides T; Nazemi KJ; Crawford J; Kilburn L; Minturn J; Gajjar A; Gauvain K; Leary S; Dhall G; Aboian M; Robinson G; Long-Boyle J; Wang H; Molinaro AM; Mueller S; Prados M
Oncotarget; 2020 May; 11(21):1942-1952. PubMed ID: 32523649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
